GM virus puts mice off sex
23 April, 2003 by Jeremy TorrAustralia's first GM mammal virus is poised to slash millions of dollars off grain spoilage figures, if medium-scale mouse-limitation trials go according to plan
Radiation technique shows good results in weight reduction trials
22 April, 2003 by Jeremy TorrInnovative RF radiation techniques have resulted in positive weight reduction results, according to a recent University of Adelaide study.
Prana sets sights on Alzheimer's diagnostic
17 April, 2003 by Jeremy TorrPossible links between the pathology of the eye and the brain have been identified by Prana consultants working on Alzheimer's patients.
New targets ID'd in hunt for clotting reduction drugs
16 April, 2003 by Melissa TrudingerMonash University scientists have identified potential new targets for the development of drugs to reduce blood clotting in patients at risk of heart attack or stroke.
EvoGenix, Genesis team to target new anti-inflammatories
15 April, 2003 by Melissa TrudingerA trans-Tasman collaboration between New Zealand's Genesis R&D and Sydney-based EvoGenix will target a novel target for anti-inflammatory therapeutics.
Genesis R&D to spin off plant division
15 April, 2003 by Melissa TrudingerNew Zealand's largest biotechnology company, Genesis Research and Development, is spinning out its plant division into a separate, fully owned company to maximise the value of its assets, according to CEO Dr Jim Watson.
Benitec licenses to US supplier Promega
11 April, 2003 by Pete YoungGene silencing company Benitec has taken a giant stride forward on the world stage by sealing a global licensing agreement for its technology with leading life sciences industry supplier Promega Corp.
Boron opens new lab, suggests IPO possible
11 April, 2003 by Melissa TrudingerMelbourne company Boron Molecular has named its new research laboratory in honour of the Japanese scientist whose reaction, the Suzuki Coupling, underpins the company's technology.
BresaGen, Plurion deal back on the drawing board
10 April, 2003 by Melissa TrudingerBresaGen's negotiations to acquire the rights to US company Plurion's embryonic stem cell technology have hit a stumbling block, sending the two companies back to the table to restructure the deal.
Agenix severs ties with US, European vet distributor
10 April, 2003 by Pete YoungBlood diagnostics company Agenix is cutting itself loose from Synbiotics, the key distributor of its veterinary diagnostic products in US and European markets.
Chairman denies Sirtex fire sale claims
09 April, 2003 by Jeremy TorrDespite rumours that Sirtex's Dr Bruce Gray is wanting to cash in his stake and sell out to established US pharma Cephalon, it appears he is still keen to steer his fledgling company towards a profitable future.
VRI board tussle intensifies
08 April, 2003 by Jeremy TorrFurther to moves by shareholder Australian Heritage Group (AHT) to shake out the board at VRI BioMedical, the war of words has intensified after a flurry of shareholder requisitions, withdrawals and accusations flying between the two companies.
Solbec board casts off its mineral past
08 April, 2003 by Jeremy TorrWestern Australian mining-turned biotech company Solbec Pharmaceuticals has severed its last links with the minerals industry in a move it has signalled as "showing the market all our past history has gone."
Ventracor gets Standard & Poor thumbs up
08 April, 2003 by Jeremy TorrArtificial heart company Ventracor has been selected by Standard & Poor as one of its basket of standard stocks used to gauge market activity.
Alchemia slashes workforce
03 April, 2003 by Pete YoungOne of the stars of Queensland’s biotech industry, biopharmaceutical company Alchemia, has sent shock waves through the sector by slashing staff by 30 per cent.
